A new marker of eosinophilic inflammation in patients with chronic obstructive pulmonary disease
- Authors: Kuznetsov V.D.1, Kozlova Y.I.1, Sobolev A.V.1, Frolova E.V.1, Uchevatkina A.E.1, Filippova L.V.1, Vasilieva N.V.1
-
Affiliations:
- I. Mechnikov North-Western State Medical University
- Issue: Vol 28, No 2 (2025)
- Pages: 235-240
- Section: SHORT COMMUNICATIONS
- URL: https://bakhtiniada.ru/1028-7221/article/view/284836
- DOI: https://doi.org/10.46235/1028-7221-17011-ANM
- ID: 284836
Cite item
Full Text
Abstract
Chronic obstructive pulmonary disease (COPD) is one of the most common bronchopulmonary diseases. Eosinophilic inflammation of the respiratory tract in COPD requires further search for new markers for diagnosis and determination of further therapy strategy. Aim: determination of periostin level and assessment of its significance as a marker of eosinophilic inflammation in patients with COPD.
The study included 45 patients with COPD (males at median age of 65). Medical history, results of clinical and instrumental studies were evaluated. The levels of total IgE and periostin were determined in blood serum by enzyme immunoassay. The obtained data were processed using the software systems STATISTICA 13 and SPSS Statistical 27.
On the basis of peripheral blood eosinophils, the patients were divided into a group with eosinophilic inflammatory endotype (9 patients, males aged 67), and a non-eosinophilic endotype (36 patients, men aged 65 years). The patients with eosinophilic endotype of COPD had a later onset of the disease [64 (61-65) years vs 56 (49-60); p = 0.011], and a significantly higher proportion of patients with a history of atopy (80% vs 0%; p < 0.001). In patients with non-eosinophilic COPD endotype, a significantly lower FEV1/FVC index was found [46 (44-51) % vs 54 (54-73) %; p = 0.019]. The serum periostin level in patients with the eosinophilic endotype of COPD was 21 (20-22) ng/mL thus being significantly higher than in the group with the non-eosinophilic endotype [14.5 (12-18) ng/mL; p = 0.008]. Using ROC analysis, it was found that a periostin value of more than 19.5 ng/mL is the optimal cut-off point for detecting the eosinophilic endotype in patients with COPD thus serving an additional potential predictor of a positive response to inhaled glucocorticosteroid therapy (ICS) [AUC was 0.940 ± 0.060 with 95% CI: 0.822-1,000, sensitivity of 80%, specificity of 80% (p = 0.007)].
Periostin is a promising marker of eosinophilic inflammation in patients with COPD. Its elevated level may be considered an additional criterion for the administration of ICS therapy.
Full Text
##article.viewOnOriginalSite##About the authors
V. D. Kuznetsov
I. Mechnikov North-Western State Medical University
Author for correspondence.
Email: valeriy_smith@inbox.ru
Postgraduate Student, Department of Clinical Mycology, Allergology and Immunology
Russian Federation, Saint PetersburgYa. I. Kozlova
I. Mechnikov North-Western State Medical University
Email: valeriy_smith@inbox.ru
PhD, MD (Medicine), Professor, Department of Clinical Mycology, Allergology and Immunology
Russian Federation, Saint PetersburgA. V. Sobolev
I. Mechnikov North-Western State Medical University
Email: valeriy_smith@inbox.ru
PhD, MD (Medicine), Professor, Department of Clinical Mycology, Allergology and Immunology
Russian Federation, Saint PetersburgE. V. Frolova
I. Mechnikov North-Western State Medical University
Email: valeriy_smith@inbox.ru
PhD (Medicine), Head, Research Laboratory of Immunology and Allergology, P. Kashkin Research Institute of Medical Mycology
Russian Federation, Saint PetersburgA. E. Uchevatkina
I. Mechnikov North-Western State Medical University
Email: valeriy_smith@inbox.ru
PhD (Medicine), Senior Researcher, Research Laboratory of Immunology and Allergology, P. Kashkin Research Institute of Medical Mycology
Russian Federation, Saint PetersburgL. V. Filippova
I. Mechnikov North-Western State Medical University
Email: valeriy_smith@inbox.ru
PhD (Medicine), Senior Researcher, Research Laboratory of Immunology and Allergology, P. Kashkin Research Institute of Medical Mycology
Russian Federation, Saint PetersburgN. V. Vasilieva
I. Mechnikov North-Western State Medical University
Email: valeriy_smith@inbox.ru
PhD, MD (Medicine), Professor, Head, Department of Medical Microbiology, Director, P. Kashkin Research Institute of Medical Mycology
Russian Federation, Saint PetersburgReferences
- Авдеев С.Н., Емельянов А.В., Айсанов З.Р. Проблемы и возможности для повышения диагностики бронхиальной астмы и хронической обструктивной болезни легких в России: заключение совета экспертов // Терапевтический архив, 2022. Т. 94, № 4. С. 524-529. [Avdeev S.N., Emelyanov A.V., Aisanov Z.R. Problems and opportunities to improve diagnosis of asthma and chronic obstructive pulmonary disease in Russia: resolution of advisory board. Terapevticheskiy arkhiv = Therapeutic Archive, 2022, Vol. 94, no. 4, pp. 524-529. (In Russ.)]
- Авдеев С.Н., Трушенко Н.В., Мержоева З.М. Эозинофильное воспаление при хронической обструктивной болезни легких // Терапевтический архив, 2019. Т. 91, № 10. С. 144-152. [Avdeev S.N., Trushenko N.V., Merzhoeva Z.M. Eosinophilic inflammation in chronic obstructive pulmonary disease. Terapevticheskiy arkhiv = Therapeutic Archive, 2019, Vol. 91, no. 10, pp. 144-152. (In Russ.)]
- Быстрицкая Е.В., Биличенко Т.Н. Заболеваемость, инвалидность и смертность от болезней органов дыхания в Российской Федерации (2015-2019) // Пульмонология, 2021. Т. 31, № 5. С. 551-561. [Bystritskaya E.V., Bilichenko T.N. The morbidity, disability, and mortality associated with respiratory diseases in the Russian Federation (2015-2019). Pulmonologiya = Pulmonologiya, 2021, Vol. 31, no. 5, pp. 551-561. (In Russ.)]
- Постникова Л.Б., Костров В.А., Болдина М.В., Зеляева Н.В. Распространенность хронической обструктивной болезни легких в крупном промышленном центре (Нижний Новгород) // Пульмонология, 2011 № 2. С. 5-8. [Postnikova L.B., Kostrov V.A., Boldina M.V., Zelyaeva N.V. Prevalence of chronic obstructive pulmonary disease in a large industrial city (Nizhny Novgorod). Pulmonologiya = Pulmonologiya, 2011, no. 2, pp. 5-8. (In Russ.)]
- Adeloye D., Chua S., Lee C. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J. Glob. Health., 2015, Vol. 5, no. 2, 020415. doi: 10.7189/jogh.05-020415.
- Bhatt S., Agusti A., Bafadhel M. Phenotypes, etiotypes, and endotypes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2023, Vol. 208, no. 10, pp. 1026-1041.
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet., 2015, Vol. 385, no. 9963, pp. 117-171.
- Lopez A., Shibuya K., Rao C. Obstructive pulmonary disease: current burden and future projections. Eur. Respir. J., 2006, Vol. 27, no. 2, pp. 397-412.
- Matsumoto H. Role of serum periostin in the management of asthma and its comorbidities. Respir. Investig., 2020, Vol. 58, no. 3, pp. 144-154.
- Nejman-Gryz P., Górska K., Paplińska-Goryca M. Periostin and thymic stromal lymphopoietin—potential crosstalk in obstructive airway diseases. J. Clin. Med., 2020, Vol. 9, no. 11, 3667. doi: 10.3390/jcm9113667.
- Park H.Y., Lee H., Koh W.J. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis., 2016, Vol. 11, no. 1, pp. 23-30.
Supplementary files
